Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1996 Jan;87(1):134–140.

Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies.

M W Boehme 1, Y Deng 1, U Raeth 1, A Bierhaus 1, R Ziegler 1, W Stremmel 1, P P Nawroth 1
PMCID: PMC1383979  PMID: 8666425

Abstract

Inflammatory cytokines decrease the expression of thrombomodulin (TM) on the endothelial cell surface by suppression of TM transcription and translation or internalization with subsequent degradation. Nevertheless, elevated serum TM levels are found in diseases associated with systemical or locally increased levels of inflammatory cytokines. To study directly the in vivo effects of tumour necrosis factor-alpha (TNF-alpha) we determined the course of serum TM after systemic recombinant human (rh)TNF-alpha therapy. The TM levels were determined by enzyme-linked immunosorbent assay (ELISA). Systemic rhTNF-alpha therapy resulted in a marked and significant increase of serum TM. Using a mouse model we studied whether increased serum TM is associated with a decreased expression of TM on the endothelial surface in vivo. The immunohistochemical staining of the vasculature of meth-A sarcoma transplanted in mice showed a loss of TM immunoreactivity 4 hr after intravenous TNF-alpha application. To study the mechanism of TNF-alpha mediated release of TM, cultured endothelial cells were incubated with neutrophils and TNF-alpha. Incubation with TNF-alpha alone did not lead to an increase of TM in vitro. However TM was released into the culture supernatant when endothelial cells pretreated with TNF-alpha were exposed to neutrophils. This was associated with morphological evidence of endothelial cell damage. Therefore, the concerted action of cytokine-stimulated endothelial cells and neutrophils results in release of TM from cultured endothelial cells after rhTNF-alpha therapy. This might explain the increased serum TM levels observed in diseases associated with increased systemic or local levels of inflammatory cytokines despite the induced internalization and the direct inhibitory effects of TNF-alpha on TM transcription and translation.

Full text

PDF
134

Images in this article

137Figure 2
on p.137
138Figure 3
on p.138

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer K. A., ten Cate H., Barzegar S., Spriggs D. R., Sherman M. L., Rosenberg R. D. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989 Jul;74(1):165–172. [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505–518. doi: 10.1146/annurev.bi.57.070188.002445. [DOI] [PubMed] [Google Scholar]
  4. Bevilacqua M. P. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767–804. doi: 10.1146/annurev.iy.11.040193.004003. [DOI] [PubMed] [Google Scholar]
  5. Bevilacqua M. P., Pober J. S., Majeau G. R., Fiers W., Cotran R. S., Gimbrone M. A., Jr Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4533–4537. doi: 10.1073/pnas.83.12.4533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boehme M. W., Nawroth P. P., Kling E., Lin J., Amiral J., Riedesel J., Raeth U., Scherbaum W. A. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1994 Apr;37(4):572–577. doi: 10.1002/art.1780370419. [DOI] [PubMed] [Google Scholar]
  7. Boehme M. W., Werle E., Kommerell B., Raeth U. Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria. Clin Investig. 1994 Aug;72(8):598–603. doi: 10.1007/BF00227452. [DOI] [PubMed] [Google Scholar]
  8. Brisson C., Archipoff G., Hartmann M. L., Hanau D., Beretz A., Freyssinet J. M., Cazenave J. P. Antibodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells. Thromb Haemost. 1992 Dec 7;68(6):737–743. [PubMed] [Google Scholar]
  9. Carlos T., Kovach N., Schwartz B., Rosa M., Newman B., Wayner E., Benjamin C., Osborn L., Lobb R., Harlan J. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood. 1991 May 15;77(10):2266–2271. [PubMed] [Google Scholar]
  10. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clauss M., Murray J. C., Vianna M., de Waal R., Thurston G., Nawroth P., Gerlach H., Bach R., Familletti P. C., Stern D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem. 1990 Apr 25;265(12):7078–7083. [PubMed] [Google Scholar]
  12. Collins C. L., Ordonez N. G., Schaefer R., Cook C. D., Xie S. S., Granger J., Hsu P. L., Fink L., Hsu S. M. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol. 1992 Oct;141(4):827–833. [PMC free article] [PubMed] [Google Scholar]
  13. Conway E. M., Boffa M. C., Nowakowski B., Steiner-Mosonyi M. An ultrastructural study of thrombomodulin endocytosis: internalization occurs via clathrin-coated and non-coated pits. J Cell Physiol. 1992 Jun;151(3):604–612. doi: 10.1002/jcp.1041510321. [DOI] [PubMed] [Google Scholar]
  14. Conway E. M., Nowakowski B., Steiner-Mosonyi M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood. 1992 Sep 1;80(5):1254–1263. [PubMed] [Google Scholar]
  15. Deguchi Y., Shibata N., Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol. 1990 Aug;81(2):311–314. doi: 10.1111/j.1365-2249.1990.tb03336.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dittman W. A., Majerus P. W. Structure and function of thrombomodulin: a natural anticoagulant. Blood. 1990 Jan 15;75(2):329–336. [PubMed] [Google Scholar]
  17. Esmon C. T., Owen W. G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2249–2252. doi: 10.1073/pnas.78.4.2249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Esmon C. T. The regulation of natural anticoagulant pathways. Science. 1987 Mar 13;235(4794):1348–1352. doi: 10.1126/science.3029867. [DOI] [PubMed] [Google Scholar]
  19. Esmon N. L., Owen W. G., Esmon C. T. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982 Jan 25;257(2):859–864. [PubMed] [Google Scholar]
  20. Fink L. M., Eidt J. F., Johnson K., Cook J. M., Cook C. D., Morser J., Marlar R., Collins C. L., Schaefer R., Xie S. S. Thrombomodulin activity and localization. Int J Dev Biol. 1993 Mar;37(1):221–226. [PubMed] [Google Scholar]
  21. Gearing A. J., Hemingway I., Pigott R., Hughes J., Rees A. J., Cashman S. J. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci. 1992 Dec 4;667:324–331. doi: 10.1111/j.1749-6632.1992.tb51633.x. [DOI] [PubMed] [Google Scholar]
  22. Gerlach H., Lieberman H., Bach R., Godman G., Brett J., Stern D. Enhanced responsiveness of endothelium in the growing/motile state to tumor necrosis factor/cachectin. J Exp Med. 1989 Sep 1;170(3):913–931. doi: 10.1084/jem.170.3.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Harlan J. M., Killen P. D., Harker L. A., Striker G. E., Wright D. G. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest. 1981 Dec;68(6):1394–1403. doi: 10.1172/JCI110390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hashimoto Y., Hirohata S., Kashiwado T., Itoh K., Ishii H. Cytokine regulation of hemostatic property and IL-6 production of human endothelial cells. Inflammation. 1992 Dec;16(6):613–621. doi: 10.1007/BF00919344. [DOI] [PubMed] [Google Scholar]
  25. Hemmer C. J., Bierhaus A., von Riedesel J., Gabat S., Liliensiek B., Pitronik P., Lin J., Grauer A., Amiral J., Ziegler R. Elevated thrombomodulin plasma levels as a result of endothelial involvement in plasmodium falciparum malaria. Thromb Haemost. 1994 Sep;72(3):457–464. [PubMed] [Google Scholar]
  26. Hirokawa K., Aoki N. Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro. J Cell Physiol. 1991 Apr;147(1):157–165. doi: 10.1002/jcp.1041470120. [DOI] [PubMed] [Google Scholar]
  27. Ishii H., Majerus P. W. Thrombomodulin is present in human plasma and urine. J Clin Invest. 1985 Dec;76(6):2178–2181. doi: 10.1172/JCI112225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ishii H., Nakano M., Tsubouchi J., Ishikawa T., Uchiyama H., Hiraishi S., Tahara C., Miyajima Y., Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost. 1990 Apr 12;63(2):157–162. [PubMed] [Google Scholar]
  29. Ishii H., Uchiyama H., Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost. 1991 May 6;65(5):618–623. [PubMed] [Google Scholar]
  30. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Karmochkine M., Boffa M. C., Piette J. C., Cacoub P., Wechsler B., Godeau P., Juhan I., Weiller P. J. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood. 1992 Feb 1;79(3):837–838. [PubMed] [Google Scholar]
  32. Kodama S., Uchijima E., Nagai M., Mikawatani K., Hayashi T., Suzuki K. One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies. Clin Chim Acta. 1990 Dec 3;192(3):191–199. doi: 10.1016/0009-8981(90)90221-d. [DOI] [PubMed] [Google Scholar]
  33. Lentz S. R., Tsiang M., Sadler J. E. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood. 1991 Feb 1;77(3):542–550. [PubMed] [Google Scholar]
  34. Lienard D., Ewalenko P., Delmotte J. J., Renard N., Lejeune F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992 Jan;10(1):52–60. doi: 10.1200/JCO.1992.10.1.52. [DOI] [PubMed] [Google Scholar]
  35. Lindahl A. K., Boffa M. C., Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost. 1993 Feb 1;69(2):112–114. [PubMed] [Google Scholar]
  36. Maruyama I., Bell C. E., Majerus P. W. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol. 1985 Aug;101(2):363–371. doi: 10.1083/jcb.101.2.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Moore K. L., Esmon C. T., Esmon N. L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989 Jan;73(1):159–165. [PubMed] [Google Scholar]
  38. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nawroth P. P., Handley D. A., Esmon C. T., Stern D. M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A. 1986 May;83(10):3460–3464. doi: 10.1073/pnas.83.10.3460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nawroth P., Handley D., Matsueda G., De Waal R., Gerlach H., Blohm D., Stern D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med. 1988 Aug 1;168(2):637–647. doi: 10.1084/jem.168.2.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Old L. J. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630–632. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
  43. Palladino M. A., Jr, Shalaby M. R., Kramer S. M., Ferraiolo B. L., Baughman R. A., Deleo A. B., Crase D., Marafino B., Aggarwal B. B., Figari I. S. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987 Jun 1;138(11):4023–4032. [PubMed] [Google Scholar]
  44. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol Rev. 1990 Apr;70(2):427–451. doi: 10.1152/physrev.1990.70.2.427. [DOI] [PubMed] [Google Scholar]
  45. Sacks T., Moldow C. F., Craddock P. R., Bowers T. K., Jacob H. S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest. 1978 May;61(5):1161–1167. doi: 10.1172/JCI109031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Smedly L. A., Tonnesen M. G., Sandhaus R. A., Haslett C., Guthrie L. A., Johnston R. B., Jr, Henson P. M., Worthen G. S. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986 Apr;77(4):1233–1243. doi: 10.1172/JCI112426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Soff G. A., Jackman R. W., Rosenberg R. D. Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood. 1991 Feb 1;77(3):515–518. [PubMed] [Google Scholar]
  48. Springer T. A. Adhesion receptors of the immune system. Nature. 1990 Aug 2;346(6283):425–434. doi: 10.1038/346425a0. [DOI] [PubMed] [Google Scholar]
  49. Suzuki K., Nishioka J., Hayashi T., Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem. 1988 Oct;104(4):628–632. doi: 10.1093/oxfordjournals.jbchem.a122523. [DOI] [PubMed] [Google Scholar]
  50. Takano S., Kimura S., Ohdama S., Aoki N. Plasma thrombomodulin in health and diseases. Blood. 1990 Nov 15;76(10):2024–2029. [PubMed] [Google Scholar]
  51. Takaya M., Ichikawa Y., Kobayashi N., Kawada T., Shimizu H., Uchiyama M., Moriuchi J., Watanabe K., Arimori S. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 1991 Sep-Oct;9(5):495–499. [PubMed] [Google Scholar]
  52. Tamura A., Matsubara O., Hirokawa K., Aoki N. Detection of thrombomodulin in human lung cancer cells. Am J Pathol. 1993 Jan;142(1):79–85. [PMC free article] [PubMed] [Google Scholar]
  53. Varani J., Bendelow M. J., Sealey D. E., Kunkel S. L., Gannon D. E., Ryan U. S., Ward P. A. Tumor necrosis factor enhances susceptibility of vascular endothelial cells to neutrophil-mediated killing. Lab Invest. 1988 Aug;59(2):292–295. [PubMed] [Google Scholar]
  54. Varani J., Ginsburg I., Schuger L., Gibbs D. F., Bromberg J., Johnson K. J., Ryan U. S., Ward P. A. Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol. 1989 Sep;135(3):435–438. [PMC free article] [PubMed] [Google Scholar]
  55. Wankowicz Z., Megyeri P., Issekutz A. Synergy between tumour necrosis factor alpha and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation. J Leukoc Biol. 1988 Apr;43(4):349–356. doi: 10.1002/jlb.43.4.349. [DOI] [PubMed] [Google Scholar]
  56. Weiss S. J., Young J., LoBuglio A. F., Slivka A., Nimeh N. F. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest. 1981 Sep;68(3):714–721. doi: 10.1172/JCI110307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Westlin W. F., Gimbrone M. A., Jr Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol. 1993 Jan;142(1):117–128. [PMC free article] [PubMed] [Google Scholar]
  58. Yamada O., Moldow C. F., Sacks T., Craddock P. R., Boogaerts M. A., Jacob H. S. Deleterious effects of endotoxin on cultured endothelial cells: an in vitro model of vascular injury. Inflammation. 1981 Jun;5(2):115–126. doi: 10.1007/BF00914201. [DOI] [PubMed] [Google Scholar]
  59. Zeck-Kapp G., Kapp A., Busse R., Riede U. N. Interaction of granulocytes and endothelial cells upon stimulation with tumor necrosis factor-alpha: an ultrastructural study. Immunobiology. 1990 Nov;181(4-5):267–275. doi: 10.1016/s0171-2985(11)80518-8. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES